Isradipine, a calcium-entry blocker, decreases vascular [125-I]low-density lipoprotein entry in hypercholesterolemic rabbits

J Cardiovasc Pharmacol. 1991 Apr;17(4):546-50. doi: 10.1097/00005344-199104000-00004.

Abstract

In 72 male rabbits aged 6 months, the endothelium of the abdominal aorta was abraded by a Fogarthy catheter. The animals were then fed a 1% cholesterol-supplemented diet for 4 weeks. In addition, half of the animals were treated for the entire period with isradipine (0.3 mg/kg daily), a dihydropyridine calcium antagonist; the other 36 animals served as controls. One hour and 3, 6, 12, 24, and 48 hours before the animals were killed, [125-I]low-density lipoprotein (LDL 10 microCi) was administered intravenously (i.v.) to six animals in each group. The [125-I]LDL entry was quantified in the abdominal aorta according to the type and presence of endothelial lining. Isradipine significantly reduced the [125-I]LDL entry at most time intervals. In parallel, an increase in vascular prostaglandin (PGI2) synthesis was noted, which might be the underlying mechanism for the decreased LDL entry.

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Blood Vessels / drug effects
  • Blood Vessels / metabolism*
  • Calcium Channel Blockers / pharmacology*
  • Epoprostenol / biosynthesis
  • Hypercholesterolemia / metabolism*
  • Iodine Radioisotopes
  • Isradipine
  • Lipoproteins, LDL / metabolism*
  • Male
  • Pyridines / pharmacology*
  • Rabbits

Substances

  • Calcium Channel Blockers
  • Iodine Radioisotopes
  • Lipoproteins, LDL
  • Pyridines
  • Epoprostenol
  • Isradipine